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Abstract  
Cardiometabolic comorbidities present a considerable burden for patients with rheumatoid 
arthritis (RA) or psoriatic arthritis (PsA). Both RA and PsA are associated with an increased risk 
of cardiovascular disease (CVD). PsA more often exhibits an increased risk of metabolically 
linked comorbidities such as obesity, insulin resistance, type 2 diabetes mellitus and non-
alcoholic fatty liver disease (NAFLD). Although both RA and PsA are characterised by a state 
of chronic inflammation, the mechanisms that contribute to CVD risk in these conditions 
might not be identical. In RA, systemic inflammation is thought to directly contribute to CVD 
risk, whereas in PsA, adiposity is thought to contribute to a notable metabolic phenotype that, 
in turn, contributes to CVD risk. Hence, appropriate management strategies that consider the 
increased risk of cardiometabolic comorbidities in patients with inflammatory arthropathy 
are important. In RA, such strategies should focus on the prediction of CVD risk and its 
management through targeting chronic inflammation and traditional CVD risk factors. In PsA, 
management strategies should focus additionally on targeting metabolic components, 
including weight management, which might not only help improve disease activity in the 
joints, entheses and skin, but also reduce the risk of metabolic comorbidities and improve the 
quality of life of patients.  
 
 
  
2 
 
Introduction 
Individuals with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) have an increased risk of 
cardiometabolic comorbidities compared with the general population1,2. The strong 
association between RA and cardiovascular disease (CVD) has been well-studied and is likely 
related to the underlying state of chronic inflammation in RA and the accompanied increase 
in several pro-inflammatory cytokines that are also involved in the pathogenesis of 
atherosclerosis3.  
 
By contrast, psoriatic disease, a term that encompasses both psoriasis and PsA, is considered 
a more metabolically-driven phenotype than RA and associated with moderately increased 
CVD risk compared with the general population1. Emerging evidence from genetics studies 
suggest a causal relationship between BMI and psoriasis4. Furthermore, weight-loss 
interventions can increase the proportion of individuals with PsA achieving minimal disease 
activity (MDA)5,6. Metabolic comorbidities including type 2 diabetes mellitus, dyslipidaemia 
and hypertension are more prominent in patients with PsA than in the general population, 
even after adjustment for BMI7. The presence of these comorbidities, in addition to 
underlying chronic inflammation, might contribute to the apparent increased CVD risk in 
patients with PsA.  
 
Chronic inflammation is a major pathogenic process in PsA, RA and potentially in primary 
atherosclerosis. Pro-inflammatory cytokines such as TNF, IL-1 and IL-17 contribute to 
atherosclerotic plaque formation and stability8. Moreover, a number of pro-inflammatory 
cytokines that contribute to PsA and RA pathogenesis, including TNF and IL-6, function 
systemically and effect numerous extra-articular tissues including skeletal muscle, adipose 
tissue, the liver and the endothelium9. As such, mediators of articular and cutaneous 
inflammation could also potentially contribute to metabolic and atherosclerotic pathology 
and as such could drive co-morbidities. 
  
In this Review, we focus on RA and PsA, two common inflammatory arthropathies that have 
a notable cardiometabolic burden; although the risk of cardiometabolic co-morbidities is also 
an important consideration for a number of other inflammatory arthropathies, including 
ankylosing spondylitis, such discussions are outside the scope of this Review. We discuss 
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evidence supporting the burden of CVD in patients with RA or PsA and outline the important 
function of underlying systemic inflammation. Furthermore, we discuss metabolic 
comorbidities including obesity, type 2 diabetes mellitus, dyslipidaemia, non-alcoholic fatty 
liver disease (NAFLD) and hypertension that occur in RA and PsA (table 1). Finally, we briefly 
review the effects of anti-rheumatic therapies on cardio-metabolic comorbidities and suggest 
directions for future research. 
 
Burden of CVD in RA and PsA  
RA is associated with increased cardiovascular morbidity and mortality relative to the general 
population1. By comparison, evidence supporting increased CVD risk in PsA is less-well 
established. The following section outlines available epidemiological data describing the 
occurrence of CVD in patients with RA or PsA, often reported as Major Adverse Cardiovascular 
Events (MACE; a composite measure that includes non-fatal myocardial infarction, non-fatal 
stroke and cardiovascular death), coronary heart disease (CHD) and cardiovascular events in 
different papers. Although data from observational studies cannot prove causality, these data 
highlight the risks associated with these conditions.  
 
Rheumatoid arthritis 
In 2012, a meta-analysis of 14 observational studies reported that individuals with RA had a 
48% higher risk of incident CVD compared with the general population10. In particular, the 
findings suggested that those with RA had a 68% higher risk of myocardial infarction and a 
41% higher risk of stroke compared with the general population. This latter finding was 
confirmed in a more recent meta-analyses in 2017, which reported a 69% higher risk of 
incident myocardial infarction in patients with RA after adjusting for age and sex11. Although 
traditional CVD risk factors (for example, smoking, obesity, physical inactivity, 
hyperlipidaemia, type 2 diabetes mellitus and hypertension) were more prevalent in patients 
with RA (as well as other forms of arthritis including PsA), the relative risk of incident 
myocardial infarction remained considerable even after adjusting for at least one of these risk 
factors11. 
 
Increased RA disease severity is thought to be associated with greater risk of CVD, supporting 
the involvement of inflammation in cardiovascular risk. For example, in a large population-
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based longitudinal cohort study, the patients with RA who had received DMARD therapy (a 
surrogate of severe disease) had a 58% higher risk of a MACE, whereas those not receiving 
DMARD therapy had a 39% higher risk, compared with the general population1. Although 
there are limitations to this definition of disease severity, cardiovascular mortality was 43% 
to 66% higher in patients with RA compared with the general population, irrespective of 
DMARD use1. 
 
Several algorithms, such as the Framingham risk score12 and the Systematic Coronary Risk 
Evaluation (SCORE)13, can be used to predict an individual’s risk of cardiovascular events 
through the incorporation of traditional CVD risk factors including age, sex, systolic blood 
pressure and cholesterol levels. However, such algorithms can underestimate the risk of CVD 
in certain groups of individuals, including patients with RA14,15. In an attempt to address this 
issue, the EULAR taskforce recommend the use of a 1.5 multiplication factor when estimating 
the risk of CVD in patients with RA using CVD risk prediction algorithms (except when using 
the QRISK3 prediction algorithm, which already incorporates a multiplication factor for 
individuals with a diagnosis of RA)16. The validity of this multiplication factor has been 
questioned by some17,18; however, this approach remains one of the best options available 
for estimating the risk of CVD in patients with RA owing to the lack of validated RA-specific 
CVD risk prediction models. Such models will be difficult to generate given the requirement 
for large cohort numbers and a long length of follow-up to generate sufficient power in CVD 
outcome studies, including model validation studies. 
 
Some researchers have suggested that the increased risk of CVD in RA is similar to that 
reported for type 2 diabetes mellitus19. However, when these two diseases were considered 
concurrently with full adjustment for other risk factors, during the development of the QRISK3 
risk prediction algorithm, the risk of CVD was much greater for patients with type 2 diabetes 
mellitus than for patients with RA, with adjusted hazard ratios (HRs) of 2.91 and 1.24, 
respectively, for type 2 diabetes mellitus and RA in women (with similar differences in men)20. 
Intriguingly, this adjusted HR for RA was less than in previous estimates, which might relate 
to the inclusion of glucocorticoid use as a separate entity. The adjusted HRs for CVD in women 
and men taking glucocorticoids were 1.81 (1.74-1.89) and 1.58 (1.5-1.66), respectively, 
emphasising the adverse cardiovascular effects of long-term steroid use. The QRISK algorithm 
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is perhaps one of the most comprehensive CVD risk algorithms and QRISK2 was one of the 
first algorithm to include RA as an independent risk factor, adding ~40-50% additional risk for 
patients with RA. However, notably, this excess risk was reduced to 1.24 in the later and more 
extensive version (QRISK3). This reduction might imply a lower excess risk than previous 
estimates because of the availability of earlier and better treatments for RA and/or because 
some of the excess risk in previous estimates was caused by steroid use. 
In summary, although CVD risk remains greater in patients with RA than in the general 
population, particularly the risk of myocardial infarction, the degree of excess risk might be 
less than previously estimated. This reduced risk might be because of improved disease 
control, as well as general improvements in the management of CVD risk in patients with 
autoimmune disease.  
 
Psoriatic arthritis 
Compared with RA, data available on the risk of CVD in patients with PsA is less well 
established and more variable. A large cohort study of the entire adult Danish population 
reported a higher rate of MACEs among patients with PsA (adjusted rate ratio 1.79; 95% CI 
1.31–2.45)21. However, in a UK population-based longitudinal cohort study of patients in 
primary care, the risk of MACEs in patients with PsA was only moderately increased compared 
with the general population (adjusted HR of 1.24; 95% CI 1.03 to 1.49 for patients with PsA 
not receiving DMARD therapy)1. In analyses of individual MACE components, PsA was 
associated with an increased risk of myocardial infarction1,22. However, whether PsA is also 
associated with an increased risk of stroke is inconsistent across different studies. Several 
studies have reported no statistically significant association between PsA and risk of 
stroke23,24, whereas another study reported a 33% higher risk of stroke in patients with PsA 
not receiving DMARD therapy1 and a meta-analysis suggested an overall 22% higher risk of 
stroke in patients with PsA22. 
 
Traditional cardiovascular risk factors contribute to overall CVD risk in PsA. For example, in 
one analysis of 1091 patients with PsA and a >35 year follow-up, hypertension (relative risk 
1.81; P=0.015) and type 2 diabetes mellitus (relative risk 2.72; P<0.001) were independent 
predictors of major cardiovascular events (defined as a composite of myocardial infarction, 
ischaemic stroke, revascularisation, or cardiovascular death)25. The extent of disease activity 
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and systemic inflammation (in women) were also independent predictors. In a subsequent 
study of patients with either psoriasis or PsA, almost 88% of the patients had at least one 
modifiable cardiovascular risk factor: 17% were current smokers, 13% had type 2 diabetes 
mellitus, 45% had hypertension, almost 50% had dyslipidaemia and >75% were overweight or 
obese26. Notably, a lapse in time between the diagnosis and treatment of co-morbidities in 
patients with PsA was also identified, with 59% of patients with hypertension and almost 66% 
of patients with dyslipidemia undertreated for these conditions. Such gaps between diagnosis 
and treatment of CVD risk factors have also been reported in RA27. 
 
In the Nord-Trøndelag Health Study (HUNT study), although the prevalence of CVD risk factors 
(including hypertension and obesity) were higher in patients with PsA than in the general 
population24, this increased prevalence did not translate into a higher 10-year risk of a fatal 
cardiovascular event, as estimated by the risk prediction algorithm SCORE24. Furthermore, in 
a separate analysis of the UK population, CVD mortality in patients with PsA was no different 
to that in the general population (adjusted HR of 1.07; 95% CI 0.79 to 1.44), although notably 
the confidence interval was wide1. 
 
Overall, although the prevalence of traditional CVD risk factors and the risk of myocardial 
infarction seem to be higher in patients with PsA than in the general population, whether 
these patients also have an increased risk of stroke is unclear. Conflicting results might in part 
relate to the small number of events recorded in some studies (and therefore an insufficient 
power to detect significant differences) or a weak association between PsA and stroke. The 
apparent discrepancy between risk of CVD events and risk of cardiovascular mortality in PsA 
is also intriguing, but might again be caused by underpowered findings.  
Inflammation and risk of CVD  
Inflammation has an important function in atherosclerotic plaque formation. An increased 
serum concentration of C-reactive protein (CRP) is associated with an increased risk of CVD in 
the general population28, suggestive of a potential link between low grade inflammation and 
risk of CVD. The heightened inflammatory state in RA and to a lesser extent in PsA might 
contribute to an increased risk of CVD in these conditions. Hence, targeting inflammation 
might reduce risk of CVD in these patients. 
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CRP and CVD  
As plasma concentrations of the acute phase reactant CRP might predict future risk of CVD29, 
several clinical trials have investigated the effect of reducing inflammation, as assessed by 
reductions in CRP concentration, on CVD outcomes, both in the general population and in 
individuals with pre-existing CVD. For example, the JUPITER (Justification for the use of statins 
in prevention: an intervention trial evaluating rosuvastatin) trial sought to ascertain whether 
individuals with increased CRP serum concentrations but without hyperlipidemia could 
benefit from statin treatment30. In this study, treatment with rosuvastatin reduced both CRP 
concentrations and the incidence of MACEs, leading the investigators to suggest that these 
findings support the hypothesis that lowering CRP concentrations also lowers the risk of CVD 
(known as the ‘inflammatory hypothesis’). However, the concentrations of low-density 
lipoprotein cholesterol (LDL-C) were also reduced with statin treatment, and other research 
suggests a near perfect linear link between LDL-cholesterol reduction and the cardiovascular 
benefits of statins31. Furthermore, in another primary prevention trial of statin treatment, 
once changes in LDL-C levels were accounted for, there was no link between statin-induced 
changes in CRP and cardiovascular benefits32. Hence, data from the JUPITER trial cannot be 
used to support the inflammatory hypothesis.  
 
Since the JUPITER trial, two landmark trials assessing the inflammatory hypothesis of 
atherothrombosis have been published, with mixed results. The Canakinumab Anti-
inflammatory Thrombosis Outcome Study (CANTOS) was the first randomized controlled 
proof-of-concept trial to show that directly reducing inflammation, through treatment with a 
monoclonal antibody against IL-1β (canakinumab; 150mg every 3 months), reduced the 
incidence of recurrent vascular events (HR 0.85; 95% CI 0.74 to 0.98; P = 0.021) independent 
of lipid-level lowering capacity33. However, in the related Cardiovascular Inflammation 
Reduction Trial (CIRT), treatment with low-dose methotrexate to reduce inflammation did not 
result in any significant difference from placebo in reducing CVD events in individuals with a 
previous myocardial infarction or multi-vessel coronary disease and who also had either type 
2 diabetes mellitus or metabolic syndrome (HR 0.96; 95% CI 0.79–1.16)34. The investigators 
argued that this discrepancy might be explained by the failure of methotrexate to lower 
concentrations of CRP, IL-1β, or IL-6; furthermore, median concentrations of CRP were also 
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much lower at baseline in CIRT than in CANTOS, such that those enrolled in CANTOS had 
higher levels of residual inflammation and might therefore have been more likely to benefit 
from treatment. Nevertheless, the results in CANTOS are the first to confirm the 
cardiovascular benefits of directly targeting inflammatory pathways. However, the benefit-
to-risk ratio and cost-effectiveness of canakinumab is not sufficient enough for this treatment 
to be considered in routine clinical practice for secondary prevention of CVD.  
 
RA, inflammation and atherosclerosis 
RA and atherosclerosis share similar underlying inflammatory pathways, including T-cell and 
mast cell activation, pro-inflammatory cytokine production and increased expression of 
leukocyte adhesion molecules35. Immune complexes and pro-inflammatory cytokines 
including TNF, IL-1β and IL-6 arise primarily from inflamed target tissues including the 
synovium, but also potentially arise from secondary lymphoid tissues such as the spleen, 
lymph nodes and adipose tissue. These pro-inflammatory mediators are released into the 
systemic circulation and have potential effects on numerous distal tissues including the 
skeletal muscle, adipose tissue (with reciprocal auto-inflammatory effects), the liver and 
blood vessel endothelium, which can result in cardiovascular risk factor modulation including 
vascular dysfunction, an compositionally and quantitatively altered lipid profile, 
prothrombotic effects and a putative increase in insulin resistance. Such effects could 
promote atherogenesis (Figure 1)9,36. 
 
Numerous studies have reported an association between RA and atherosclerotic burden, with 
patients with RA having an increased carotid intima-media thickness and carotid plaque 
burden compared with age-matched and sex-matched individuals without a history of CVD 37. 
Furthermore, coronary plaques were more prevalent in patients with RA (71%) than age-
matched and sex-matched individuals without an autoimmune disease (45%), as was multi-
vessel disease38. Notably, in patients with RA, a higher disease activity was associated with a 
higher risk of non-calcified and mixed plaques (composed of both calcified and non-calcified 
components), which seem more vulnerable and prone to rupture than fully calcified plaques 
38,39.  
Imaging using combined PET and CT scanners and the tracer fluorodeoxyglucose (FDG-PET/CT 
imaging) can be used to directly visualise arterial wall inflammation and measure 
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atherosclerotic plaque activity40 . In a small study that compared 17 patients with RA with 34 
patients with stable cardiovascular disease, the patients with RA had a higher aortic uptake 
of FDG, reflecting higher vascular wall inflammation, which was lowered with anti-TNF 
therapy41. In a larger study of 91 patients with RA, aortic inflammation (assessed by FDG-
PET/CT imaging) in RA was associated with a higher BMI, hypertension and the presence of 
rheumatoid nodules; surprisingly, aortic inflammation negatively correlated with anti-CCP 
antibody positivity42. However, this study was cross-sectional and observational in design 
meaning that causality could not be assessed. Nevertheless, increasing evidence supports the 
association between RA and the presence of more (perhaps unstable) coronary plaques38.  
 
The current evidence base linking RA to atherosclerosis mostly come from small studies and 
should be interpreted with caution owing to publication bias (that is, a skewing of the 
literature towards studies with positive results, which are more easily published than negative 
results). Future work should include larger studies that adjust for existing cardiovascular risk 
factors and include a fuller representation of the range of RA including differing severities, 
treatment states and disease duration. These studies are important in the modern era given 
the improvements in disease outcomes in patients over the years, potentially because of 
better management of systemic inflammation.  
 
PsA, inflammation and atherosclerosis 
Several cytokines implicated in psoriatic disease might contribute to atherosclerosis through 
shared chronic inflammatory pathways, including T helper 1 (TH1) and TH17 cell activation, 
pro-inflammatory cytokine release and local and systemic adhesion molecule expression. For 
example, the concentration of TH1-associated cytokines (TNF, IFNγ and IL-2) and TH17-
associated cytokines (IL-17A, IL-17F, IL-22, IL-26 and TNF) is increased in the circulation and 
lesional skin of individuals with psoriasis or PsA compared with individuals without these 
conditions43. These pro-inflammatory cytokines might have effects on distant organs 
including adipose tissue, the liver, skeletal muscle and endothelium, leading to chronic 
systemic inflammation and a pro-atherogenic profile (figure 1).  
 
In particular, circulating levels of TNF, either alone or in combination with IL-17, have been 
associated with endothelial dysfunction8. Several adhesion and pro-inflammatory molecules 
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associated with CVD are produced by monocytes after exposure to IL-1744. Indeed, IL-17-
driven inflammation is a potential immunological link between psoriatic disease and 
increased CVD risk44. Similar to in patients with RA, high levels of IL-6 in patients with PsA 
could promote synovitis and bone erosion45. Finally, in agreement with a potential function 
of IL-6 in CVD, some polymorphisms in the gene encoding IL-6 are associated with CVD 
outcomes46,47.  
 
To explain the link between systemic inflammation and CVD in PsA, investigators have 
proposed the concept of the ‘psoriatic march’ whereby systemic inflammation in psoriasis 
causes insulin resistance, which then leads to endothelial dysfunction, atherosclerosis and 
eventual CVD48. A similar pathway possibly also occurs in RA. Obesity might contribute to a 
state of chronic inflammation in PsA through the release of adipokines, including leptin and a 
variety of pro-inflammatory cytokines (such as IL-6 and TNF), from adipose tissue48. Although 
this idea is interesting, on the population level, obesity is thought to contribute to CVD risk 
mainly via affecting lipid concentrations, blood pressure and the occurrence of type 2 
diabetes mellitus49. 
 
Several small studies have reported an association between PsA and subclinical 
atherosclerosis. Flow-mediated dilatation, a potential marker of endothelial function, was 
impaired in patients with PsA compared with age-matched and sex-matched individuals 
without PsA, and carotid artery intima-media thickness was also greater in patients with PsA 
than in controls50,51. In 2018, one study assessed the relationship between PsA, metabolic 
syndrome and coronary plaque burden using coronary computed tomography angiography52. 
Coronary plaques were present in 76% of patients with PsA compared with 44% of age-
matched and sex-matched individuals without PsA, with greater total plaque volume and 
higher prevalence of mixed plaques in PsA. This latter finding is clinically relevant as mixed 
plaques contain a thin cap fibroatheroma, which is associated with myocardial ischaemia and 
a poorer prognosis53. Furthermore, the presence of metabolic syndrome in PsA was not 
associated with quantitative measure of plaque burden (including segment involvement 
score, segment stenosis score, total plaque volume) and plaque composition, whereas 
markers of PsA disease severity, including maximum tender joint count, ESR, and CRP 
concentration, were associated with plaque burden (segment involvement score and 
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segment stenosis score). However, caution is advised in interpreting these findings as the 
study sample size was small (25 patients with PsA and metabolic syndrome and 25 patients 
with PsA without metabolic syndrome) and had a cross-sectional design. A combination of 
traditional risk factors and disease activity probably contribute to an increased CVD burden 
in PsA. 
 
Metabolic co-morbidities in RA and PsA  
Metabolic comorbidities represent a considerable burden in PsA, and, perhaps to a lesser 
degree, in RA (Figure 2). These comorbidities include dyslipidaemia (pathogenic changes in 
lipid levels), obesity, impaired glucose tolerance and subsequent type2 diabetes mellitus, 
NAFLD and hypertension. Many studies exploring the association between RA or PsA and 
comorbidities are largely observational in design and therefore residual confounding and 
reverse causality cannot be fully excluded.  
 
Dyslipidaemia  
In the general population, a classic dyslipidaemic profile, consisting of abnormally high serum 
concentrations of total cholesterol and LDL-C, as well as serum triglycerides, and abnormally 
low serum concentrations of high-density lipoprotein cholesterol (HDL-C), is firmly associated 
with an increased risk of coronary heart disease (CHD)54. Indeed, a 1mmol/L reduction in LDL-
C with statin therapy is associated with a ~20% reduction in MACEs55, with more intensive 
reductions in LDL-C resulting in further reductions in risk of CVD, even in individuals who had 
low serum concentrations of LDL-C before treatment56. 
However, in some patients with RA, a ‘lipid paradox’ exists in which active disease seems to 
be associated with lower serum concentrations of total cholesterol and LDL-C, despite RA 
being an independent risk factor of CVD57. Similar changes in total cholesterol and LDL-C also 
occur in patients with active PsA, but these patients also have additional features indicative 
of metabolic disturbances, such as obesity or insulin resistance, low concentrations of HDL-C 
and high concentrations of triglycerides58.  
 
Rheumatoid arthritis 
The mechanism by which systemic inflammation in RA leads to lipid alterations is 
incompletely understood. One hypothesis is that the inflammatory response in active RA 
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leads to activation of the mononuclear phagocyte system that ‘scavenges' LDL particles, 
hence lowering serum LDL-C concentrations.  
 
Supporting this hypothesis, treatment to reduce inflammation in general leads to a rise in 
serum LDL-C concentrations59; in particular, treatment with the IL-6 receptor antagonist 
tocilizumab is associated with notable increases in total cholesterol, LDL-C and triglyceride 
concentrations60. The reasons for this finding seem to be linked to a reversal of IL-6-induced 
LDL-C clearance from the circulation61. Similar patterns of lipid changes have been observed 
across the studies of JAK inhibitors, which inhibit signalling downstream of IL-657,62,63. For 
example, treatment of patients with RA with tofacitinib, a JAK inhibitor, results in reduced 
clearance of LDL-C particles from the circulation and an increase in circulating cholesterol 
concentrations 64. 
 
Aside from quantitative changes in some lipid particles, inflammation is also associated with 
changes in the composition of lipid particles and although a lot of research has been done in 
this area, the implications of these changes remain uncertain65,66.  
 
Psoriatic arthritis 
Total cholesterol, HDL-C and LDL-C levels are often lower and triglyceride levels higher in 
patients with PsA relative to those without PsA2. For example, one study reported that 
patients with active PsA had lower mean total cholesterol concentrations than age-matched 
and sex-matched individuals from the local population ((4.99mmol/L versus 6.08mmol/L, 
respectively), as well as lower mean LDL-C concentrations (3.3 mmol/L versus. 4.12mmol/L, 
respectively) and HDL-C concentrations (1.12mmol/L versus 1.29mmol/L, respectively)67. 
Such findings were also observed in another study, with patients with PsA having lower total 
cholesterol and LDL-C concentrations68. A reduction in cholesterol and LDL-C concentrations 
is in keeping with active inflammation, but notably, the pattern of reduced HDL-C and 
increased triglyceride concentrations is more prevalent in patients with PsA than in patients 
with RA58. As this profile is often associated with obesity and type 2 diabetes mellitus, this 
finding is in keeping with PsA having a more metabolic phenotype than RA. 
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Adiposity 
Increased adiposity is associated with CVD mortality and morbidity, which is thought to be 
caused largely via the effect of obesity on lipids, blood pressure and diabetes risk. For every 
5-unit increase in BMI in individuals with a BMI >25kg/m2, the risk of dying from CVD increases 
by 49%69. Obesity is strongly associated with increased risk of metabolic comorbidities, which 
occur more commonly in psoriasis and PsA than in RA and include hypertension, type 2 
diabetes mellitus, dyslipidaemia and NAFLD. Notably, central adiposity, as assessed by waist 
circumference, is potentially a better marker of future risk of type 2 diabetes, especially in 
women70, and is also more linearly associated with risk of incident CVD, than BMI71.  
 
Rheumatoid arthritis 
Evidence supporting a contribution of adiposity to RA pathology is mixed. In a small case-
control study that compared 165 individuals with RA from the Norfolk Arthritis Register with 
age-matched and sex-matched healthy individuals, obesity (a BMI >30kg/m2) was associated 
with a three-fold higher risk of RA72. However, a later larger study of the UK General Practice 
Research Database (GPRD) that compared 579 individuals with incident RA with 4,234 age-
matched and sex-matched individuals without RA found no association between obesity and 
risk of RA73. More recent findings from a large population-based cohort study that analysed 
data from >500,000 individuals (the UK Biobank) suggest that an increased waist 
circumference is associated with greater odds of RA even after adjustment for BMI74.  
 
Unlike in the general population, patients with RA who are overweight (BMI 25.0–29.9 kg/m2) 
or obese (BMI >30.0 kg/m2) have a lower relative risk of all-cause and CVD mortality than 
patients with a normal BMI (18.5–24.9 kg/m2), a phenomenon known as the ‘obesity 
paradox’75. Being underweight (BMI <18.5 kg/m2) is also associated with a higher all-cause 
mortality and CVD mortality in patients with RA76. Notably, this inverse association between 
BMI and mortality disappears after adjustment for co-morbidities and RA severity77. 
Therefore, the obesity paradox of RA could relate to residual confounding and reverse 
causality whereby active inflammatory disease leads to unintentional weight loss75. This 
hypothesis is supported by the finding that weight loss, rather than current BMI, is a strong 
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predictor of mortality in RA, with a fall in BMI of ≥1kg/m2 associated with almost twice the 
risk of death78. 
 
Although BMI is often used to define obesity, this index cannot provide any detail on body 
composition. Consideration of body composition might be important as individuals with an 
apparently ‘normal’ BMI (<25 kg/m2) can have different proportions of fat and lean mass, 
which might have cardiovascular effects. For example, women with RA have a lower lean mass 
but also an increased body fat mass compared with women without RA (termed at its extreme 
as ‘sarcopenic obesity’), which is most apparent in women with a BMI in the normal range. 
Although data suggest a similar trend in men with RA, including greater odds of sarcopenia, 
high body fat, and a sarcopenic obesity phenotype compared with men without RA, this trend 
was not statistically significant or as pronounced as in women. This sex difference might relate 
to a higher prevalence of key predictors of sarcopenia (such as joint deformity and physical 
inactivity) in women than in men, as well as the possible influence of hormonal factors; 
however, the difference might also relate to the low statistical power of the findings79. 
 
Knowledge of the distribution of body fat might also be useful as an increased amount of 
ectopic adipose tissue is associated with a higher risk of CVD and metabolic diseases (in 
particular, type 2 diabetes)80, and some evidence suggest that men with RA have a higher 
visceral adipose tissue area than men without RA, despite having a similar waist 
circumference and BMI81. Further research is needed to assess the true clinical implications 
of an altered body composition in RA. Notably, in clinical practice, BMI measurements 
dominate and few, if any, doctors regularly measure body composition of patients, probably 
because BMI is often considered together with other clinical information to help place the 
results into context. Furthermore, compared with weight measurements, measurements of 
body composition are less accurate and precise meaning that changes are harder to assess. 
 
Psoriatic arthritis 
Obesity is more prevalent in patients with PsA than in the general population82, which might 
contribute to an increased CVD risk in these patients. Obesity is strongly associated with an 
increased probability of developing PsA83. For example, in a study of the UK general 
population, individuals with psoriasis and a BMI ≥35kg/m2 had a 48% higher risk of developing 
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PsA than individuals with psoriasis and a BMI <25kg/m2, after adjustment for conventional 
risk factors84. In a secondary analysis of all individuals, regardless of psoriasis status, having a 
BMI ≥35kg/m2 almost doubled the chance of an individual having PsA compared with 
individuals with a BMI <25kg/m2. The associations between BMI and PsA are even more 
pronounced in other studies, including a reported 6-fold higher risk of developing PsA for 
women with a BMI >35kg/m 2 85.  
 
Obesity seems to have a greater association with late-onset PsA or psoriasis and in individuals 
who are HLA-B27 haplotype negative86. Notably, psoriasis has two peaks of onset: type I 
psoriasis (onset <40 years old) and type II psoriasis (onset >40 years old)87,88. Comparing the 
pathogenesis of both subtypes, type I psoriasis seems to have a stronger genetic and 
autoimmune component (similar to type I diabetes mellitus), whereas type II psoriasis seems 
to have a stronger involvement of obesity (similar to type 2 diabetes mellitus89). Additional 
studies are needed to examine these associations further.  
 
Such associations do not prove causality and whether BMI is causally linked to PsA or psoriasis 
development cannot be ascertained from observational data alone. In 2019, researchers used 
genotyping (as a proxy for BMI measurements) of samples from the UK Biobank or HUNT 
study and a mendelian randomization approach to test for such a causal relationship. The 
data suggested that a higher BMI increased the risk of psoriasis (OR= 1.09 per 1 kg/m2), with 
little evidence for causality in the opposite direction4. This directional association is supported 
by findings of improved disease activity in patients who had lost weight through dietary 
interventions5,6. Indeed, a ≥5% loss in body weight in patients starting treatments with TNF 
inhibitors, irrespective of the type of dietary intervention, predicted an achievement of 
minimal disease activity (MDA) 5. In another study, the introduction of a very low energy diet 
(VLED; 640kcal/day) for 12-16 weeks in 41 patients with PsA and a BMI ≥ 33 kg/m2, which led 
to a median weight loss of 18.7 kg (18.6% of initial weight), resulted in 54% of the patients 
achieving MDA6. Interestingly, gastric bypass surgery is associated with a lower incidence of 
PsA (adjusted HR 0.29 (95% CI, 0.12-0.71)90. Further prospective trials are needed to fully 
assess the effect of weight loss interventions on PsA outcomes. 
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Type 2 diabetes 
The association between type 2 diabetes mellitus and CVD is well established. Type 2 diabetes 
mellitus is associated with an almost 200% higher risk of peripheral arterial disease, a 72% 
higher risk of ischaemic stroke and a 54% higher risk of non-fatal myocardial infarction than 
the general population91. Emerging evidence suggests that the incidence and prevalence of 
type 2 diabetes mellitus is higher in individuals with psoriatic disease than in the general 
population92, which contributes to a metabolic phenotype and increased risk of CVD in these 
patients. By contrast, whether type 2 diabetes mellitus is more common in RA is less clear. 
 
Rheumatoid arthritis 
The data on RA and type 2 diabetes mellitus are conflicting. In one report, the incidence of 
diabetes was higher in a cohort of 48,718 individuals with RA (incidence rate (IR) 8.6 per 1,000 
person-years; 95% CI 8.5 – 8.7)) than in a cohort of 442,033 individuals without any known 
rheumatic disease (IR 5.8 per 1,000 person-years; 95% CI 5.8–5.8)), suggesting that individuals 
with RA have a ~50% higher risk of diabetes93. However, the researchers of this study did not 
adjust for BMI. In a later study by Dubreuil et al.92, assessing the incidence of diabetes among 
individuals with PsA, psoriasis or RA, the risk of incident diabetes among the 11,158 
individuals with RA was higher than in age-matched and sex-matched individuals without RA 
(unadjusted HR of 1.12; 95% CI 1.01–1.25); however, this increased risk was lost after 
adjusting for BMI, smoking and alcohol use (HR 0.94; 95% CI 0.84–1.06) 92. Overall, as obesity 
is less common in patients with RA than in patients with PsA, links to metabolic dysfunction 
per se are less apparent.  
 
Psoriatic arthritis 
PsA is associated with higher incidence of type 2 diabetes. In the study by Dubreuil et al.92, 
the risk of new onset diabetes was 72% higher in the 4,196 individuals with PsA than in the 
age-matched and sex-matched individuals without psoriatic disease (HR 1.72; 95% CI 1.46–
2.02)). Notably, adjustment for BMI, smoking, alcohol, baseline steroid use and co-morbidities 
attenuated this association (adjusted HR 1.33; 92% Cl 1.09–1.61), highlighting the important 
contribution of obesity and lifestyle factors to diabetes risk in patients with PsA. A higher 
disease activity is also associated with a higher risk of developing diabetes in patients with 
PsA94. Such work suggests PsA is a risk factor for Type 2 diabetes.  
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Similar to in the general population, several traditional risk factors including hypertension, 
dyslipidemia, and obesity are associated with an increased risk of type 2 diabetes in patients 
with PsA; interestingly, in one study, a later age of onset of psoriasis (>40 years) was more 
strongly linked to diabetes than a younger age of disease onset, implying the existence of 
potentially different disease phenotypes and supporting the argument that screening for 
diabetes is more informative in those individuals who develop psoriasis later in life95. 
Data from mouse models of psoriasis-like skin disease suggest a pathophysiological link 
between dysglycaemia and psoriatic disease. For example, in two such mouse models, 
inhibition of glucose uptake in keratinocytes through genetic or chemical inhibition of the 
GLUT1 transporter reduced skin inflammation and epidermal hyperproliferation96, 
highlighting a potential future treatment strategy for psoriasis96. 
 
Non-alcoholic fatty liver disease 
NAFLD includes a spectrum of liver diseases from non-alcoholic fatty liver (NAFL) to non-
alcoholic steatohepatitis (NASH), and can include complications such as hepatic steatosis 
(accumulation of fat in the liver) and fibrosis (scarring of the liver) that eventually leads to 
cirrhosis and potentially carcinoma in a small number of individuals. NAFLD affects >20% of 
the general population and is associated with obesity and the development of type 2 diabetes 
mellitus97.  
 
Psoriatic disease is associated with an increased prevalence of NAFLD98. In a cohort of 142 
patients with psoriasis attending a health-care centre in Italy, 84 (59%) had evidence of 
NAFLD99. NAFLD in these patients correlated with metabolic syndrome, obesity, 
hypertriglyceridemia, hypercholesterolaemia and PsA, providing further support for a strong 
metabolic phenotype in PsA. An increased risk of NAFLD in individuals with psoriasis was also 
reported in a meta-analysis of 7 case-control studies (OR: 2.15 95% CI: 1.57–2.94), even when 
only the high quality studies were analysed98. The risk of NAFLD was higher in individuals with 
PsA than in individuals with psoriasis (OR: 2.25, 95% CI: 1.37–3.71), and was also higher in 
individuals with moderate to severe psoriasis than in individuals with mild psoriasis (OR: 2.07, 
95% CI: 1.59–2.71).  
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Whether the occurrence of NAFLD in some individuals with PsA or RA is treatment-related or 
influenced by the severity of disease itself is unclear. In a comprehensive analysis of UK 
primary-care data analysing the risk of liver disease in patients prescribed or not prescribed a 
systemic therapy, compared with the general population, the risk of NAFLD was higher in 
patients with psoriasis, regardless of whether they were being treated with a systemic 
therapy (HR 1.18 and 2.23 for untreated and treated patients, respectively). NAFLD risk was 
also higher for treated patients with PsA (HR 2.11), with a trend towards greater risk in 
untreated patients with RA (HR 1.20)100. Moreover, risks of cirrhosis were highest in treated 
patients with psoriasis and in untreated patients with PsA. These findings concur with a higher 
average BMI and a more pronounced metabolic perturbations (for example, excess liver fat) 
in patients with psoriasis or PsA than in patients with RA or the general population and also 
suggest such patients should be warned of their increased risk of liver disease and to keep 
alcohol intake to a minimum. The data should also help doctors encourage their patients to 
consider making even small but sustainable lifestyle changes to improve weight trajectories.  
 
Blood pressure 
Increased blood pressure is a causal risk factor of CVD, with a 10 mmHg reduction in systolic 
blood pressure associated with a 20% reduction in CVD events, a 17% reduction in CHD, a 27% 
reduction in stroke and a 28% reduction in heart failure risk101. Hence hypertension, defined 
as a blood pressure >140/90mmHg, potentially contributes to the risk of CVD in patients with 
RA or PsA.  
 
Rheumatoid arthritis 
Hypertension is a well-known cardiovascular risk factor in RA. In a large international cross-
sectional study (the comorbidities in rheumatoid arthritis (COMORA) study) that included 
4,586 patients with RA in 17 countries, the prevalence of hypertension in RA was estimated 
at 40.4%102. Data from UK Biobank suggested that individuals with self-reported RA have a 
41% higher risk of hypertension compared with individuals without RA103, which was 
attenuated to 19% after adjustment for conventional risk factors.  
Overall, such evidence suggests that patients with RA have higher blood pressures than the 
general population, which could be because of the chronic effects of excess systemic 
cytokines on the structure of blood vessels and/or the effects of some therapies used to treat 
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RA. For example, an observational study of over 21,000 patients with RA reported that, 
compared with commencing methotrexate, commencing leflunomide was more strongly 
associated with a notable increase in blood pressure (SBP >20mmHg or DBP >10 mm Hg) (OR 
1.37; 95% CI, 1.24–1.451), and an increased risk of developing hypertension (HR 1.52 (95% CI; 
1.21–1.91))104. By contrast, those patients starting methotrexate were 9% more likely to 
achieve an optimal blood pressure (<130/90 mmHg) after 6 months of treatment. 
 
Psoriatic arthritis 
Similar to RA, hypertension is more prevalent in patients with PsA than in the general 
population. In a prospective study of 648 patients with PsA (using data from the Canadian 
Community Health Survey), the prevalence of hypertension was higher than in the general 
population (standardised prevalence ratio 1.90; 95% CI 1.59-2.27)23. In a separate meta-
analysis, individuals with PsA were more than twice as likely to have hypertension than 
individuals without PsA (OR 2.07 (1.41-3.04))105. However, interpretation of these findings is 
limited because of the substantial heterogeneity in the studies included in the analysis, 
including differences in study populations, outcome assessments and varying use of 
adjustments for confounders.  
 
The exact mechanisms linking psoriatic disease and hypertension are unknown. Both 
conditions share several risk factors, including high BMI and smoking, but the association 
seems to remain even after adjustment for these factors. Higher quality studies, including the 
longitudinal measurement of blood pressure in patients with psoriasis of PsA, are needed to 
further investigate this relationship. 
 
The effects of anti-rheumatic therapies 
Systemic inflammation is central to RA, PsA and atherosclerosis pathogenesis. Therefore, 
minimising disease activity with effective anti-rheumatic therapies, which is recommended 
by current EULAR guidelines16, should lower the risk of cardiometabolic comorbidities (Box 
1). The following section outlines the effect of current anti-rheumatic therapies on 
cardiometabolic outcomes (Box 2). Most evidence comes from observational pharmaco-
epidemiology studies, principally of patients with RA as evidence for patients with PsA is more 
limited. Caution should always be applied when interpreting pharmaco-epidemiology studies 
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because of the potential for residual confounding and allocation bias, which is impossible to 
fully adjust for. 
 
NSAIDs  
Non-selective NSAIDs inhibit two recognised forms of cyclooxygenases (COX, also known as 
prostaglandin G/H synthase), COX1 and COX2, and include ibuprofen, naproxen, and 
diclofenac. These non-selective NSAIDs have anti-inflammatory effects, probably mediated 
by inhibition of COX2, and gastrointestinal adverse effects, mediated by inhibition of COX1. 
To avoid these adverse effects, selective COX2 inhibitors have also been developed, including 
etoricoxib and celecoxib106.  
 
NSAID therapy is associated with increased blood pressure, although this association might 
be specific to individual NSAIDs. For example, in one trial of patients with arthritis, treatment 
with ibuprofen increased the mean 24-hour systolic blood pressure (SBP) of the patients by 
3.7mmHg, whereas celecoxib and naproxen had no effect107. 
NSAIDs, notably diclofenac (a non-selective COX inhibitor) and the selective COX-2 inhibitors 
rofecoxib and celecoxib, are associated with increased cardiovascular risk (such as myocardial 
infarction and CHD death), particularly at higher doses108,109. Rofecoxib was withdrawn in 
2004 because of safety concerns; in one randomised trial, treatment with this COX2 inhibitor 
was associated with almost twice the risk of cardiovascular thrombotic events compared with 
placebo treatment110. This increased risk could be caused by several effects mediated by 
COX2 inhibition including a reduction in prostacyclin concentrations, an increase in blood 
pressure, a decrease in angiogenesis and atherosclerotic plaque destabilization 110. By 
contrast, a large well-conducted meta-analysis of trial data found that treatment with high-
dose naproxen resulted in no excess risk of major cardiovascular events (relative risk 0.93; 
95% CI 0·69–1·27)109 . 
 
In a separate meta-analysis that included observational data, NSAID use was associated with 
an 18% higher risk of all cardiovascular events (CVEs) in patients with RA. The investigators 
concluded that COX2 inhibitors probably drove this effect, as the risk of CVE was not increased 
in a subgroup analysis of non-selective NSAIDs alone. In line with this supposition, in a study 
of over 17,000 patients with RA, treatment with rofecoxib or diclofenac was associated with 
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a notable increase in risk of CVD (HR 1.57 (95% CI 1.16-2.12) and HR 1.35 (95% CI 1.11-1.64), 
respectively), whereas other NSAIDs, including naproxen, ketoprofen and nabumetone, were 
not111. Compared with studies in patients with RA, less is known about the effects of NSAIDs 
on CVD risk in patients with PsA.  
 
Corticosteroids 
Although corticosteroids are very effective at treating inflammation in patients with RA, these 
drugs have notable long-term effects on morbidity and mortality. Notably, long term use of 
oral steroids for any individual (whether or not they have RA) was associated with an 82% and 
58% higher cardiovascular risk in women and men, respectively20, which was likely in part 
related to the detrimental effects of these drugs on cardiometabolic factors. For example, 
corticosteroid use increases the risk of type 2 diabetes, hypertension, thrombotic stroke or 
myocardial infarction and death in patients with RA112,113.  
 
Some of the reported effects of steroid use on cardiovascular outcomes, however, could 
potentially be caused by confounding by indication and hence might disappear after 
correcting for disease activity114. Furthermore, in patients with active disease, some of these 
effects might be counteracted by the anti-inflammatory benefits of these drugs, such as a 
treatment-mediated reduction in underlying inflammation and improvement of mobility. To 
help address this question, a trial is underway (the Glucocorticoid Low-dose Outcome in 
Rheumatoid Arthritis Study (GLORIA) trial) to assess the safety profile of low doses of the 
corticosteroid prednisolone in patients with RA115. Notably though, in a previous study, high 
doses of prednisolone (≥8mg daily) increased the cardiovascular mortality of patients with RA 
(HR 2.27 (95% CI 1.36–3.79), even after adjusting for propensity to receive glucocorticoids116.  
 
Conventional synthetic DMARDs 
Methotrexate use is associated with a 60% reduction in risk of all-cause mortality in patients 
with RA, including a notable reduction in risk of CVD mortality117. In one meta-analysis of 
observational studies of patients with RA, psoriasis or polyarthritis, methotrexate use was 
associated with a 21% lower risk of total CVD and a 18% lower risk of myocardial infarction118. 
This potential impact of methotrexate use was apparently greater after adjustment for 
disease severity (relative risk 0.64; 95% CI 0.43-0.96) and other concomitant medications 
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(relative risk 0.73; 95% CI 0.63-0.84). Similarly, in a systematic review, methotrexate use was 
associated with a 28% lower risk of all CVEs and a 19% lower risk of myocardial infarction in 
patients with RA119.  
 
Taken at face value, these observational findings suggest that methotrexate use might reduce 
cardiovascular risk through dampening inflammation. However, in the CIRT trial, treatment 
with low-dose methotrexate did not reduce the rate of cardiovascular events in patients with 
established CVD, leading some to question whether methotrexate is cardioprotective. It 
should be noted though that the serum concentrations of CRP were substantially lower in the 
participants of CIRT than that reported for patients with RA or PsA34. 
 
Conventional synthetic DMARDs (csDMARDs) might also have metabolic effects, including 
altering body weight and risk of diabetes. For example, treatment with either methotrexate, 
prednisone or a TNF inhibitor is associated with weight gain, whereas leflunomide treatment 
is associated with modest weight loss in RA120. In observation studies of patients with RA, 
those patients taking hydroxychloroquine or abatacept were less likely to develop diabetes, 
and those patients taking glucocorticoids were more likely to develop diabetes, than patients 
taking methotrexate monotherapy121,122. 
 
Small-molecule and biologic therapies  
Anti-TNF therapy is effective at lowering inflammation and improving disease activity in 
patients with RA or PsA123,124. As systemic inflammation drives cardiovascular risk in both 
conditions, TNF inhibition should also lower this risk.  
 
In one observational study of patients with RA, the rate of myocardial infarction was similar 
in patients taking a TNF inhibitor to patients taking csDMARDs (after adjustment for baseline 
risk factors)125. However, the rate of myocardial infarction was 64% lower in the patients who 
clinically responded to anti-TNF therapy within 6 months than the anti-TNF non-responders, 
consistent with the notion that suppressing inflammation might lower cardiovascular risk. 
Unfortunately, the investigators did not assess DAS28 scores at 6 months in the patients 
undergoing csDMARD therapy, preventing the assessment of whether lowering RA disease 
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activity per se was associated with a decreased incidence of myocardial infarction, or whether 
this effect was specific to anti-TNF therapy. 
 
In a meta-analysis, anti-TNF therapy was associated with a 54% lower risk of all CVEs, a 19% 
lower risk of myocardial infarction and a 31% lower risk of stroke compared with csDMARD 
therapy in patients with RA126. This meta-analysis had a few limitations (including analysis of 
a small number of studies, many of which were observational in design, and a high clinical 
and methodological heterogeneity); however, similar findings were reported in a larger meta-
analysis, with anti-TNF inhibitor use being associated with a lower risk of all CVEs, myocardial 
infarction, strokes and major adverse cardiac events in patients with RA119. 
 
In addition to TNF inhibitors, other biologic drugs are also effective at targeting inflammation 
in RA, including abatacept (a co-stimulation inhibitor) and tocilizumab (an IL-6 receptor 
blocker). In one comparison of the cardiovascular effects of various biologic drugs in older 
patients with RA (mean age 64 years), the risk of acute myocardial infarction was higher 
among patients initiating treatment with an anti-TNF inhibitor, in particular etanercept or 
infliximab, compared with patients initiating treatment with abatacept127. By contrast, the 
risk of CHD was similar for patients being treated with tocilizumab compared with patients 
being treated with abatacept. However, these findings should be interpreted with caution 
owing to the retrospective design of the study, the small event numbers in some of the groups 
and the lack of RA disease severity markers. Such limitations might have confounded the 
results for certain biologics; for example, a preferential use of anti-TNF therapy for patients 
with severe disease might have resulted in an overall higher disease activity in this group than 
in the other groups. The lipid profiles of the patients were also not reported in the study, 
which is important as a risk-associated lipid profile might have influenced the decision to 
prescribe tocilizumab and potentially caused selection bias (that is, clinicians might have been 
less likely to prescribe this therapy in patients with existing hyperlipidaemia and/or increased 
CVD risk).  
 
Some therapies for RA can also have metabolic effects. For example, treatment with 
tocilizumab or tofacitinib in patients with RA is associated with an increase in total cholesterol 
and LDL-C concentrations towards that of individuals without RA, probably owing to IL-6 
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inhibition60,64. Whether this effect is part of a compensatory response to dampened 
inflammation or has long-term cardiovascular sequelae remains to be fully determined. 
However, in a short observational study (mean follow up <1year), the cardiovascular risk of 
patients undergoing treatment with a TNF inhibitor was similar to patients who had switched 
to tocilizumab128. Furthermore, in a prospective phase IV cardiovascular outcome trial 
(ENTRACTE), the risk of incident MACE was the same for patients undergoing tocilizumab 
treatment and for those undergoing etanercept treatment (HR 1.05, CI 0.77 to 1.43) 129. TNF 
inhibition is also potentially associated with a lower risk of new onset diabetes mellitus than 
csDMARD therapy in patients with RA or psoriasis130. For patients with RA or ankylosing 
spondylitis, some evidence suggest that TNF-inhibition might result in a gain in weight, with 
a shift to the visceral region131. However, this study included only 20 patients with no control 
group. Hence, further studies in this area, including the potential CVD consequences of TNF 
inhibition, are needed. 
 
Unlike therapies for RA, evidence of the effect of novel therapies for PsA on cardiometabolic 
outcomes are limited. Treatment with apremilast (an oral phosphodiesterase-4 (PDE-4) 
inhibitor) is associated with modest weight loss132,133. A clinical trial (The Immune Metabolic 
Associations in Psoriatic Arthritis (IMAPA) study) is currently underway to investigate the 
cardiometabolic and immune effects of apremilast in patients with PsA134. In terms of IL-17 
inhibition, 52 weeks of secukinumab treatment improved flow-mediated dilation (FMD) in 
patients with psoriasis135. However, FMD is only a weak surrogate marker of future risk of 
CVD, and is not accepted as such by licensing authorities; formal trials of cardiovascular 
outcome with these newer agents are currently lacking.  
 
Conclusions  
The notion that patients with RA have an excess risk of CVD, even after accounting for 
traditional risk factors, is now well-established. Overwhelming evidence support the idea that 
systemic inflammation drives this excess risk both directly and by affecting several other risk 
factors. With the decline of steroid use and emergence of better treatment options in RA, 
CVD risk should fall over time. However, the relevance of the rise in LDL-C concentration 
following treatment with some anti-rheumatic drugs remains uncertain. Clinically, CVD risk 
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scoring should now be a regular part of RA management, taking advantage of the RA 
multiplier in risk scores. Modifiable CVD risk factors, including dyslipidaemia and blood 
pressure, should be managed as aggressively in patients with RA as in the general population. 
Notably blood pressure targets in individuals with an increased cardiovascular risk are now 
even lower than before136.  
 
In PsA, evidence supporting excess cardiovascular risk in patients is limited; although, some 
evidence suggest that for patients with severe disease, CVD risk might reach the same extent 
as in RA. Clinical judgement is needed for deciding when to use a CVD risk multiplier. Obesity 
and associated metabolic outcomes (such as diabetes and NAFLD) are more common in 
patients with PsA than in the general population. Multiple strands of evidence also support 
the contribution of obesity to the pathophysiological process in some patients with PsA, 
particularly in late-onset disease, with weight loss being associated with a lower disease 
activity. Accordingly, more work is needed to investigate the clinical benefits of different 
weight loss strategies in this condition. 
 
In terms of the effect of anti-rheumatic therapies, the majority of evidence, albeit 
predominantly observational in nature, suggests that treatment with a TNF inhibitor or 
methotrexate lowers the risk of CVD, whereas treatment with corticosteroids or some NSAIDs 
increases the risk of CVD in patients with RA. Some evidence suggests that CVD risk varies 
depending on the biologic used, but this notion requires further study. Targeting 
inflammation with biologics or methotrexate might therefore have positive cardiovascular 
effects in RA, supporting the idea that the systemic inflammatory response might be causally 
linked to CVD. However, the effect of targeting inflammation in PsA on cardiometabolic 
outcomes requires further study.  
 
Overall, these findings highlight the importance of a holistic, multisystem approach to the 
management of RA and PsA, not only to lessen clinically evident joint and/or skin-associated 
disease but also to improve life expectancy and quality of life. 
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Review Criteria 
A search for studies published up to January 2019 and focusing on cardiometabolic 
comorbidities in rheumatoid and psoriatic arthritis was performed in PubMed. The search 
terms used were “rheumatoid arthritis” or “psoriatic arthritis” with either “cardiometabolic”, 
“cardiovascular”, “dyslipidaemia”, “adiposity”, “diabetes”, “NAFLD”, “blood pressure”, 
“hypertension”, “DMARDs”, “TNF-inhibitors”, “corticosteroids”, or “NSAIDs”. All articles 
identified were English-language, full-text papers. We also searched the reference lists of 
identified articles for further relevant papers. 
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Key points 
 Cardio-metabolic comorbidities represent a notable morbidity and mortality burden 
in patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA)  
 Patients with RA have a higher risk of cardiovascular disease (CVD) than individuals of 
the general population; however, some of this increased risk might be driven by 
steroid use.  
 PsA is more strongly linked to metabolic co-morbidities, including obesity, NAFLD and 
type 2 diabetes mellitus. 
 Dampening inflammation with methotrexate or TNF-inhibitors might lower the 
cardiovascular risk of patients with RA, but formal randomised controlled trials are 
currently sparse.  
 In PsA, weight loss might reduce disease severity and/or risk of PsA development, but 
future prospective studies are needed to assess the effects of lifestyle interventions 
and/or pharmacologically-induced weight loss.  
 Clinical trials assessing the long-term effects of new drugs for treatment of RA or PsA 
on cardiovascular outcomes are warranted, including the safety and benefits of these 
treatments. 
 
Box 1: Treatment strategies for cardiometabolic comorbidities in RA and PsA 
Rheumatoid arthritis  
 Treat systemic inflammation with conventional synthetic DMARDs and biologic drugs 
 Assess cardiovascular risk factors, including non-fasting lipids levels and blood 
pressure, and manage modifiable risk factors when absolute CVD risk, as assessed by 
an appropriate risk prediction algorithm, is above target thresholds, or single risk 
factors are sufficiently high to merit treatment.  
Psoriatic arthritis 
 Treat underlying systemic inflammation with conventional synthetic DMARDs and 
biologic drugs 
 Consider the use of weight loss interventions, particularly in those overweight or 
obese 
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 Consider to screen for diabetes if the patient is not known to have diabetes and has 
not been recently tested. 
 Continue to address traditional CVD risk factors and treat when the absolute CVD risk 
is above target threshold  
 
Box 2. Effect of anti-rheumatic therapies on cardiometabolic outcomes 
NSAIDs 
 NSAID use can increase systolic blood pressure (SBP) and overall cardiovascular risk; 
however, this effect might depend on the NSAID used107. 
  Ibuprofen use is associated with increased SBP in patients with rheumatoid arthritis 
(RA) or osteoarthritis107. 
 Treatment with diclofenac or rofecoxib (now withdrawn) is associated with an 
increased risk of cardiovascular disease (CVD) in patients with RA109.  
 Treatment with naproxen was not associated with an increased risk of CVD in RA or 
the general population111. 
 
Corticosteroids 
 In the general population, corticosteroid use is associated with increased SBP, weight, 
insulin resistance, cardiovascular risk and all-cause mortality112,113. 
 
Conventional synthetic DMARDs (csDMARDs)  
 Methotrexate use has been associated with a lower cardiovascular risk and a lower 
all-cause mortality in observational studies of patients with RA117,. 
 Treatment with leflunomide or apremilast is associated with modest weight loss in 
individuals with RA or PsA, respectively, compared with treatment with other 
csDMARDs120,132,133. 
 The risk of developing diabetes seems lower with hydroxychloroquine use than with 
methotrexate use in patients with RA121,122. Ongoing trials are testing the effects of 
hydroxychloroquine on cardiovascular outcomes137  
 
Biologic drugs and small molecule inhibitors  
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 The risk of CVD in patients with RA seems to be lower for patients undergoing TNF-
inhibitor therapy than for patients undergoing csDMARD therapy126. 
 Treatment with either tocilizumab or tofacitinib is associated with increased 
concentrations of LDL-cholesterol60,64; larger clinical trials are needed to determine 
the long-term cardiovascular effects of such lipid changes.  
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Figure 1. Potential relationship between systematic inflammation in RA and PsA and 
cardiovascular risk  
Several pro-inflammatory cytokines, including TNF, IL-1β and IL-6, chemokines and immune 
complexes are released into the circulation from the synovial tissue, bone marrow of inflamed 
joints or associated lymph nodes. These molecules affect a number of distant tissues. Damage 
to the vascular tissue can result in arterial wall inflammation, endothelial dysfunction and 
arterial stiffness, which are, collectively, markers of subclinical damage and precursors to 
atherosclerosis and, ultimately, coronary heart disease. Increased systemic cytokines can 
directly impede insulin-mediated glucose uptake in skeletal muscle and cause skeletal muscle 
atrophy, impairing the functional capacity of the muscles and potentially leading to insulin 
resistance. Systemic inflammation might contribute to altered body composition, including 
increased central fat deposition and reduced lean mass. IL-6 production in rheumatoid 
arthritis (RA) can increase the synthesis of fibrinogen and other procoagulants in the liver, 
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contributing to a hypercoagulable state. Finally, although high-grade systemic inflammation 
results in a meaningful decline in circulating LDL cholesterol (LDL-C) and HDL cholesterol (HDL-
C) concentrations, some evidence suggests that these changes are caused by increased 
peripheral catabolism of lipids, presumably by cells of the activated reticuloendothelial 
system. There are also multiple qualitative changes in lipids. The relevance of such 
inflammation-associated lipid changes to cardiovascular risk in these conditions is not well 
established. aSome drugs influence lipid levels, but the impact this influence has on 
cardiovascular disease risk is uncertain. CRP, C-reactive protein; PsA, psoriatic arthritis. 
 
 
Figure 2. Potential relationship between cardiovascular and metabolic comorbidities in RA 
and PsA  
Both rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are characterized by systemic 
inflammation, which can contribute to an increased risk of cardiovascular disease (CVD) and 
metabolic disturbances. RA is associated with a high risk of CVD, probably owing more to 
chronic systemic inflammation than metabolic disturbances per se, but the impact of changes 
in body composition or insulin resistance on CVD risk is uncertain. By contrast, PsA is strongly 
associated with a dysfunctional metabolic profile (such as obesity and increased risk of type 
2 diabetes mellitus), particularly in patients who develop the disease in later life, which might 
indirectly increase the risk of CVD in these patients. However, individuals who develop PsA at 
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a younger age might have a larger inflammatory drive and a less obvious metabolic phenotype 
than patients with an older age of disease onset, and so inflammation might be relatively 
more important to CVD risk in these patients. NAFLD, non-alcoholic fatty liver disease. 
 
Table 1. Cardio-metabolic comorbidities in rheumatoid arthritis and psoriatic arthritis 
Cardio-metabolic 
comorbidities 
Rheumatoid arthritis 
 
Psoriatic arthritis References 
Cardio-metabolic outcomesa  
Risk of CVD 
 
 
++ + 1,10,11,21 
Obesity  
 
 
+/- ++ 4,73,74,79,84 
Type 2 diabetes  
 
 
+/- ++ 92–95 
Hypertension  
 
 
+ + 23,102,103,105 
NAFLD 
 
 
+/- ++ 98–100 
Lipid profiles in patients with active diseaseb  
Total cholesterol 
 
↓  ↓ 57,58 
LDL-C ↓ ↓ 57,61 
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HDL-C ↓ ↓ 58,66 
aCompared with individuals of the general population 
bCompared with individuals in remission or without disease 
++ markedly increased; + increased; +/- mixed evidence. 
↑ increased; ↓ decreased.  
Rheumatoid arthritis (RA); Psoriatic arthritis (PsA); Cardiovascular disease (CVD); Body Mass 
Index (BMI); Non Alcoholic Fatty Liver Disease (NAFLD); low-density lipoprotein cholesterol 
(LDL-C); high-density lipoprotein cholesterol (HDL-C). 
